Skip to Main content Skip to Navigation
Journal articles

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

Abstract : Circulating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial liquid biopsies to enable tumor genome analysis throughout the course of treatment. We investigated cfDNA and mutant ctDNA as potential biomarkers to predict the best outcomes of regorafenib-treated metastatic colorectal cancer (mCRC) patients. We analyzed longitudinally collected plasma cfDNA of 43 mCRC patients prospectively enrolled in the phase II TEXCAN trial by IntPlex qPCR. Qualitative (KRAS, NRAS, BRAFV600E mutations) and quantitative (total cfDNA concentration, mutant ctDNA concentration, mutant ctDNA fraction) parameters were correlated with overall survival (OS) and progression-free survival (PFS). When examined as classes or continuous variables, the concentrations of total cfDNA, mutant ctDNA, and partly, mutant ctDNA fraction prior to regorafenib treatment correlated with OS. Patients with baseline-cfDNA >26 ng/mL had shorter OS than those with cfDNA value below this threshold (4.0 vs 6.9 months; logrank P=0.0366). Patients with baseline mutant ctDNA >2 ng/mL had shorter OS than those with mutant ctDNA below this threshold (logrank P=0.0154). We show that pre-treatment cfDNA and mutant ctDNA levels may identify mCRC patients that may benefit from regorafenib treatment.
Document type :
Journal articles
Complete list of metadata

https://hal.sorbonne-universite.fr/hal-03216431
Contributor : Gestionnaire Hal-Su <>
Submitted on : Tuesday, May 4, 2021 - 8:56:07 AM
Last modification on : Monday, May 10, 2021 - 10:48:00 AM

File

1878-0261.12972.pdf
Publication funded by an institution

Identifiers

Citation

Brice Pastor, André Thierry, Julie Henriques, Isabelle Trouilloud, Christophe Tournigand, et al.. Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. Molecular Oncology, Elsevier, 2021, ⟨10.1002/1878-0261.12972⟩. ⟨hal-03216431⟩

Share

Metrics

Record views

45

Files downloads

3